Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Change in Receivables (2016 - 2025)

BioCorRx's Change in Receivables history spans 15 years, with the latest figure at $40714.0 for Q3 2025.

  • For Q3 2025, Change in Receivables rose 219.01% year-over-year to $40714.0; the TTM value through Sep 2025 reached $39234.0, up 167.02%, while the annual FY2024 figure was -$740.0, 97.86% up from the prior year.
  • Change in Receivables for Q3 2025 was $40714.0 at BioCorRx, up from -$34210.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $168020.0 in Q4 2021 and bottomed at -$76657.0 in Q3 2022.
  • The 5-year median for Change in Receivables is $2572.0 (2022), against an average of $13848.9.
  • The largest annual shift saw Change in Receivables soared 33704.0% in 2021 before it plummeted 1884.14% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $168020.0 in 2021, then plummeted by 41.04% to $99070.0 in 2022, then crashed by 158.34% to -$57801.0 in 2023, then surged by 40.81% to -$34210.0 in 2024, then skyrocketed by 219.01% to $40714.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Change in Receivables are $40714.0 (Q3 2025), -$34210.0 (Q3 2024), and $32730.0 (Q2 2024).